NCT05858528 HIPPOCRATES Prospective Observational Study
| NCT ID | NCT05858528 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Oxford |
| Condition | Psoriatic Arthritis |
| Study Type | OBSERVATIONAL |
| Enrollment | 25,000 participants |
| Start Date | 2023-06-27 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 25,000 participants in total. It began in 2023-06-27 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
HIPPOCRATES is an Innovative Medicines Initiative (IMI) funded EU Consortium established to address key unmet clinical needs in psoriatic disease. As part of the project, the HIPPOCRATES Prospective Observational Study (HPOS) is a study of patients with psoriasis which will run across Europe. The study will be led by a research team at University of Oxford and supported by a team at University College Dublin. We are aiming to identify people with psoriasis who are at risk of developing psoriatic arthritis. Up to one-third of patients with psoriasis will develop a related arthritis causing inflammation in the joints and tendons. We want to identify which patients will develop arthritis with the long-term and ambitious aim of trying to prevent the development of arthritis before it occurs. We are recruiting/approaching adults with psoriasis and asking study participants to complete questionnaires every 6 months via a dedicated study website. The questionnaires will include a 'screening questionnaire' to try to identify arthritis. If participants are identified by the 'screening questionnaire' as having possible arthritis, they will be advised to seek local medical help. We will follow up with them to see if they are diagnosed with psoriatic arthritis. Alongside the questionnaire information from participants, we will ask some participants to provide a blood fingerprick sample using an easy to use at home sampling kit. The blood sample will be posted to a central location (University College Dublin) where it will be stored and then studied in the laboratory to look for markers that may predict the onset of arthritis. As many (most) participants will not develop arthritis, we are also studying the impact of psoriasis on the participants to learn more about how psoriasis affects people's daily lives across Europe.
Eligibility Criteria
Inclusion Criteria: * Adult ≥18 years * Self-reported diagnosis of skin psoriasis (any form) * Participant is willing and able to give informed consent for participation in the study and complete data in one of the HPOS languages Exclusion Criteria: • Pre-existing diagnosis of PsA
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05858528 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Psoriatic Arthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05858528 currently recruiting?
Yes, NCT05858528 is actively recruiting participants. Contact the research team at laura.coates@ndorms.ox.ac.uk for enrollment information.
Where is the NCT05858528 trial being conducted?
This trial is being conducted at Oxford, United Kingdom.
Who is sponsoring the NCT05858528 clinical trial?
NCT05858528 is sponsored by University of Oxford. The trial plans to enroll 25,000 participants.